Health Canada has approved Shire Pharma’s Vyvanse for the treatment of moderate-to-severe binge eating disorder in adults.
Vyvanse provides a new treatment option to Canadian physicians in addition to the psychotherapies that are currently available to treat adults with moderate-to-severe binge eating disorder.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Ottawa Hospital Regional Centre for the Treatment of Eating Disorders director Dr Hany Bissada said: “Binge eating disorder is a serious mental illness with devastating impacts, including on one’s self-esteem.
“Affected patients tend to present with other serious psychological conditions such as depression and anxiety, or conditions associated with metabolic syndrome, like diabetes for example.”
Binge eating is recognised as a distinct disorder in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition and is defined as recurring episodes of consuming more food in a short time.
During a binge eating episode, patients feel a lack of control and distress over their eating.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe disorder occurs in men, as well as women and is more common than anorexia and bulimia combined and can also occur in normal weight, overweight, and obese adults.
Shire Canada general manager Eric Tse said: “We are pleased to make this new treatment option available in Canada, and hopefully help address some of the unmet needs of Canadian adults living with moderate-to-severe binge eating disorder.”
